sintilimab: Clinical Trials

74 trials of sintilimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 recruiting, 19 completed, 18 unknown, 9 not yet recruiting. 74 Phase 1, 36 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 174Recruiting 21, Completed 19, Unknown 18, Not yet recruiting 9, Terminated 4, Active not recruiting 2, Withdrawn 1
Phase 236Recruiting 13, Unknown 9, Not yet recruiting 8, Completed 3, Active not recruiting 2, Withdrawn 1

Follow sintilimab: new trials by email Literature Review of sintilimab trials Research Report on sintilimab

Trials (filtered) newest first · largest first

All 74 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
SYS6090 Injection + Bevacizumab Injection, SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection, Bevacizumab Injection + Sintilimab Injection - HCC - Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2882026-09-302026-08-12
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
BRII-5395, Sintilimab, Bevacizumab - Advanced HBV-Related Hepatocellular Carcinoma
Phase 1RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences212026-08-122026-08-31
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
IBI310+ sintilimab + bevacizumab, IBI310+ sintilimab, sintilimab + bevacizumab - Resectable Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingShanghai Zhongshan Hospital902026-07-202026-07-20
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin - Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
Phase 1Not yet recruitingHaisco Pharmaceutical Group Co., Ltd.2582026-07-012026-07-14
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
IBI3005, Sintilimab, Bevacizumab biosimilar - Solid Tumor
Phase 1 / Phase 2Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.2822026-06-012026-05-28
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS
Sintilimab - HIV, AIDS
Phase 1 / Phase 2Not yet recruitingShanghai Public Health Clinical Center502026-05-012026-05-12
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingBinYong Liang1002026-04-302026-04-13
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
GV20-0251, Sintilimab - Head and Neck Squamous Cell Carcinoma HNSCC
Phase 1RecruitingWest China Hospital92026-04-012026-03-25
Study of ABO2102 in KRAS-Mutated Solid Tumors
ABO2102 Injection, Sintilimab injection - Advanced / Metastatic Solid Tumor
Phase 1RecruitingSuzhou Abogen Biosciences Co., Ltd.1012026-03-242026-04-06
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
IBI343, Sintilimab, Oxaliplatin - Gastric Cancer
Phase 1 / Phase 2RecruitingRuijin Hospital552025-06-022026-08-18
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + cisplatin (GP), Sintilimab injection - Advanced Intrahepatic Cholangiocarcinoma
Phase 1 / Phase 2RecruitingZhejiang University302025-04-092025-05-04
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
individualized anti-tumor new antigen iNeo-Vac-R01 injection, mFOLFIRINOX Treatment Regimen, Sintilimab injection - Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
Phase 1 / Phase 2Not yet recruitingZhejiang University302025-04-012025-03-21
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + Capecitabine, Sintilimab injection - Pancreatic Cancer Resectable
Phase 1 / Phase 2Not yet recruitingZhejiang University602025-04-012025-03-21
Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC
IBI310(1mg/kg), sintilimab, bevacizumab - Hepatocellular Carcinoma
Phase 1RecruitingShanghai Zhongshan Hospital502025-03-062026-11-17
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
Sintilimab and Linperlisib Combination Treatment - Extranodal Natural Killer/T Cell Lymphoma
Phase 1RecruitingSun Yat-sen University122025-02-212025-03-13
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
Anlotinib combined with Sintilimab - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Phase 1 / Phase 2RecruitingFujian Provincial Hospital292024-12-232025-01-07
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Bortezomib Injection, Sintilimab, mFOLFIRINOX - Pancreas Cancer
Phase 1 / Phase 2RecruitingFirst Affiliated Hospital of Zhejiang University632024-11-152025-01-10
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Propranolol hydrochloride, Sintilimab, Chemotherapy - Non Small Cell Lung Cancer, Propranolol
Phase 1 / Phase 2RecruitingSecond Xiangya Hospital of Central South University1182024-11-132026-11-19
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
AK112, Cadonilimab, AK127 - Hepatocellular Carcinoma
Phase 1 / Phase 2RecruitingAkeso2802024-09-242026-03-04
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Sintilimab, IBI110, Paclitaxel - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingFudan University272024-06-262025-02-25

Showing 20 of 74. Sign in to see all of them.

Conditions studied

Carcinoma, Hepatocellular (9)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Stomach Neoplasms (5)  ·  Neoplasms (3)  ·  Colorectal Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma of Lung (1)  ·  Endometrial Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Melanoma (1)  ·  Meningeal Carcinomatosis (1)  ·  Neoplasm Metastasis (1)

Sponsors

Innovent Biologics (Suzhou) Co. Ltd. (22)  ·  Fudan University (4)  ·  Shanghai Zhongshan Hospital (4)  ·  Sun Yat-sen University (3)  ·  West China Hospital (3)  ·  Zhejiang University (3)  ·  Beijing Tsinghua Chang Gung Hospital (2)  ·  Ruijin Hospital (2)  ·  Sichuan University (2)  ·  Akeso (1)  ·  BinYong Liang (1)  ·  CSPC Megalith Biopharmaceutical Co.,Ltd. (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Chinese PLA General Hospital (1)  ·  First Affiliated Hospital of Zhejiang University (1)

Countries

China (67)  ·  Australia (2)  ·  United States (2)  ·  France (1)  ·  Germany (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Ying Cheng (2)  ·  You Lu, MD (2)  ·  Zhen Zhang, M.D, PH.D (2)  ·  Ba Yi (1)  ·  Darren Shafren (1)  ·  Fang Meiyu (1)  ·  Gong Li, MD (1)  ·  Guo Hongqian (1)  ·  Guo Wei (1)  ·  Ji Zhu, M.D. (1)  ·  Jin Li (1)  ·  Jun Zhang (1)  ·  Kangshun Zhu, Dr. (1)

Results publications

PMID 20728210, PMID 24094768, PMID 25240821, PMID 26884585, PMID 30718072, PMID 32372672, PMID 32795349, PMID 33070260, PMID 34659886, PMID 34877867, PMID 35352512, PMID 35647908, PMID 35747712, PMID 35995696, PMID 36505833, PMID 36628898, PMID 37828033, PMID 38214075, PMID 39134346, PMID 39806128, PMID 40046248, PMID 41005780, PMID 41423492, PMID 41513419, PMID 41540424, PMID 42736273